Enovis Corporation reported $2.30B of revenue over the trailing twelve months, +4.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.30B (to Q2 2026). Net income: −$1.10B, trailing twelve months to Q2 2026. Free cash flow: $64M, trailing twelve months to Q2 2026. Operating margin: −46%, trailing twelve months to Q2 2026.

ENOVEnovis Corporation

Healthcare

$17.71-45% 1Y

$17.71

$17.4452 weeks$32.87

ENOV as reported

Enovis Corporation reported $2.30B of revenue over the trailing twelve months, +4.9% on the year before. 11 reported series are charted on this page, each one as filed.

$2.30B

Revenue, trailing twelve months · to Q2 2026 · +4.9% against the twelve months before

Net income: −$1.10B
Net income · +33% year on year · trailing twelve months to Q2 2026
Free cash flow: $64M
Free cash flow · −1711% year on year · trailing twelve months to Q2 2026
Operating margin: −46%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ENOV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.30B	+4.9%	Q2 2026
Net income	−$1.10B	+33%	Q2 2026
EPS	−$19.27	+29%	Q2 2026
Gross margin	61%	n/a	Q2 2026
Operating margin	−46%	n/a	Q2 2026
Net margin	−49%	n/a	Q2 2026
ROE	−75%	n/a	Q2 2026
ROA	−30%	n/a	Q2 2026
ROIC	−31%	n/a	Q2 2026
Free cash flow	$64M	−1711%	Q2 2026
P/E	61.5	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.